XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
   Pharmacotherapy
   Radiotherapy
   Vaccination
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Therapy Channel
subscribe to Therapy newsletter

Latest Research : Cancer : Therapy

   DISCUSS   |   EMAIL   |   PRINT
A SDF-1 Receptor Antagonist Shows Significant Reduction of Metastatic Lung Nodules Associated with Osteosarcoma
Mar 20, 2005, 08:15, Reviewed by: Dr.

CTCE-9908 binds competitively to the receptors on cancer cells which prevents the interaction of SDF-1 with the receptors. A recently completed Phase I study of this compound in healthy adults did not reveal any significant toxicity.

 
Chemokine Therapeutics Corp., a biotechnology company developing drugs in the field of chemokines and cytokines, has announced that investigators at the National Cancer Institute (NCI) reported a two-thirds reduction in the number of visible metastatic lung nodules using the Company's investigational drug CTCE-9908 in a pre-clinical study of osteosarcoma.

The study results are consistent with a pre-clinical study of CTCE-9908 conducted by researchers at Chemokine Therapeutics. CTCE-9908 is designed to inhibit the growth and spread of certain common cancers with the potential for use with existing therapies (chemotherapy, surgery, and radiation) to improve treatment outcomes.

Osteosarcoma is a form of bone cancer which can spread (metastasize) to the lungs, bone marrow and liver.

The NCI findings will be the subject of a Poster Session on April 17th at the American Association for Cancer Research (AACR) 2005 Annual Meeting to be held in Anaheim, California. The abstract is available on Chemokine Therapeutics' website. The Company will announce additional information after the poster presentation at the American Association for Cancer Research Conference.

Recently, researchers discovered that the growth and spread of cancer are affected by a chemokine known as stromal cell-derived factor-1 (SDF-1). SDF-1 is produced naturally in organs such as the bone marrow, liver, and lungs and is an important regulator of stem cells.

SDF-1 acts on receptors which are expressed in both stem cells and various common cancers. The presence of these receptors on cancer cells allows the cancerous cells to migrate from the original cancer site to new sites that are rich in SDF-1, such as bone marrow, liver, and lungs, where they develop new blood vessels (angiogenesis) and form new tumors (metastases).

CTCE-9908 is an analog of SDF-1 and antagonist of SDF-1 receptors developed by scientists at Chemokine Therapeutics using rational-drug design.

CTCE-9908 binds competitively to the receptors on cancer cells which prevents the interaction of SDF-1 with the receptors. A recently completed Phase I study of this compound in healthy adults did not reveal any significant toxicity.

Chemokine has been collaborating with the National Cancer Institute's Pediatric Oncology Branch since February, 2004. The NCI continues to evaluate the oncological potential of CTCE-9908. The NCI is a component of the National Institutes of Health (NIH), one of eight agencies that compose the Public Health Service (PHS) in the Department of Health and Human Services (DHHS).

The NCI, established under the National Cancer Act of 1937, is the principal agency for cancer research and training of the United States federal government.
 

- National Cancer Institute
 

Chemokine Therapeutics

 
Subscribe to Therapy Newsletter
E-mail Address:

 

Chemokine Therapeutics is a biotechnology company developing drugs in the field of chemokines and cytokines, a family of small, soluble proteins, which signal stem cell transport and growth into mature cells. These stem cells are master primitive cells, capable of producing billions of mature cells necessary for repair and regeneration. Chemokines and cytokines also play an important role in cancer and autoimmune disorders which can paradoxically contribute to the survival and growth of such diseases. The Company has two product candidates in clinical trials; CTCE-0214, for immune system recovery, and CTCE-9908, to prevent the spread of cancer and its continued growth. In addition, Chemokine maintains a drug discovery program to identify new chemokine-based drug candidates. Pharmaceutical Product Development, Inc. (PPDI) and Procter & Gamble Pharmaceuticals, Inc. have signed strategic agreements with Chemokine to collaborate on research and development. For more information, please visit the related website.

For more information, contact:
Ian Harper
Chemokine Therapeutics
Phone: (604) 822-0305
E-mail: [email protected]
Fax: (604) 822-0302


Related Therapy News

Genomic signatures to guide the use of chemotherapeutics
CDK2/FOXO1 as drug target to Prevent Tumors
Telomerase inhibitors may revolutionize cancer therapy
First ever shots of the cervical cancer vaccine administered in Queensland
Gleevec can be toxic to the heart
Anti-cancer possibilities seen for certain monoamine oxidase inhibitors
AS101 protects the testis from the effects of paclitaxel
Microbeam Radiation Therapy (MRT) Could Improve Cancer Treatment
Novel EGFR antibody mAb 806 targets tumors but not normal tissues
Oral chemotherapy option soon for cancer


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us